IDH2 and glioma: In conclusion, our study established the clinical, PD and translational rationale to select a late-stage molecule to target one of the most prevalent mutations in LGGs and provides a rich data resource to advance our understanding of the role of IDH mutations and the mechanism of action of IDH inhibitors in recurrent gliomas.